ClinicalTrials.gg
CompletedNCT06135168Updated Apr 3, 2025

A Clinical Trail to Compare Pharmacokinetics of Two PEG-rhGH Injections With Different Preparations

A Phase 1 interventional study of PEG-rhGH with new preparation and PEG-rhGH with present preparation in Pediatric Growth Hormone Deficiency (PGHD), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this study is to compare the pharmacokinetics of the two different PEG-rhGH preparations after a single administration.

02

Conditions studied

  • Pediatric Growth Hormone Deficiency (PGHD)
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male aged ≥18 years old and≤45 years old;
  • The (BMI): 19-26 kg/m2 (inclusive), and body weight ≥50 kg;
  • Normal results of physical examination, vital signs, laboratory tests, 12 lead-, chest X-ray, abdominal ultrasound, or non-clinical significance changes in the assessments above.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a history of reactions or hypersensitivity reactions to drugs containing;
  • Subjects with a clear history of disorders of the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system, metabolic system, etc., or other diseases deemed unsuitable for participation in the trials by the investigators;
  • Subjects with severe infection, severe trauma, or major surgery prior to screening;
  • Subjects who have received blood transfusions, had blood donors, or lost blood before screening;
  • Subjects who have positive results of antibodies (HIV-Ab), or surface antigen (HBsAg), or virus antibodies (HCV-Ab), or syphilis specific antibodies (TPPA);
  • Subjects who have participated in clinical trials for medication or medical device prior to screening;etc.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    PEG-rhGH with new preparation

    Drug: PEG-rhGH with new preparation

  • Experimental
    PEG-rhGH with present preparation

    Drug: PEG-rhGH with present preparation

Interventions

  • DrugPEG-rhGH with new preparation

    A single subcutaneous injection of PEG-rhGH with new preparation

  • DrugPEG-rhGH with present preparation

    A single subcutaneous injection of PEG-rhGH with present preparation

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (Peak Plasma Concentration (Cmax)) of PEG-rhGH with present and new preparation

    Time frame: 0 hours -168 hours

  2. Pharmacokinetics (The area under the concentration time curve from time zero to time infinity(AUC0-∞)) of PEG-rhGH with present and new preparation

    Time frame: 0 hours -168 hours

  3. Pharmacokinetics (the area under the concentration-time curve from time zero to time t (AUC0-t))of PEG-rhGH with present and new preparation

    Time frame: 0 hours -168 hours

Secondary outcomes

  1. Pharmacokinetics (the time to reach the peak drug concentration(Tmax) of PEG-rhGH with present and new preparation.

    Time frame: 0 hours -168 hours

  2. Pharmacokinetics (half-life (t1/2)) of PEG-rhGH with present and new preparation.

    Time frame: 0 hours -168 hours

  3. Pharmacokinetics (terminal elimination rate constant (λz)) of PEG-rhGH with present and new preparation.

    Time frame: 0 hours -168 hours

  4. Safety and tolerability (Number of participants with treatment-related adverse events)

    Time frame: 0 hours -168 hours

  5. Safety and tolerability (Number of Participants with Abnormal Laboratory Values and/or Vital Signs That Are Related to Treatment)

    Time frame: Day1 0 hours and Day 8 168 hours

  6. Safety and tolerability (Number of Participants with Abnormal 12-lead ECG QTc Interval That Are Related to Treatment)

    Time frame: Day1 0 hours and Day 8 168 hours

  7. Safety and tolerability (Number of Participants with Abnormal Laboratory Values That Are Related to Treatment)

    Time frame: Day1 0 hours and Day 8 168 hours

Other outcomes

  1. Anti-drug antibody (Number of Participants with positive ADA)

    Time frame: 0 hours -168 hours

07

Study locations

1 site
  • Chengdu Xinhua Hospital affiliated to North Sichuan Medical College
    Chengdu, Sichuan 610000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Nov 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 18, 2023
StartActual
Oct 31, 2023
Primary completionActual
Nov 29, 2023
CompletionActual
Mar 18, 2024
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06135168
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Oct 31, 2023
Primary completion
Nov 29, 2023
Completion
Mar 18, 2024
Last update
Apr 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion